Nature Reviews Cancer

Article	Citations
Computing brain metastasis impact	723
Fructose takes a detour to feed cancer	694
Combining spatial transcriptomics and AI to enhance brain tumour diagnosis	498
Combinatorial strategies to target RAS-driven cancers	494
Implementing practice-changing progress for managing cancer of unknown primary	476
Emerging strategies to investigate the biology of early cancer	437
Claudin proteins as emerging therapeutic targets for solid tumours	386
Oncofetal reprogramming in tumour development and progression	378
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment	327
INVADEseq to study the intratumoural microbiota at host single-cell resolution	318
Exploiting metabolic cell death for cancer therapy	305
Mapping the prostate cell family tree	301
Fighting cancer with fat	292
Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’	280
The recruitment of metastasis-associated monocytes	269
3D chromatin architecture as a predictor of somatic mutations in cancer genomes	268
Connie J. Eaves (1944–2024)	264
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies	261
Translating premalignant biology to accelerate non-small-cell lung cancer interception	255
Avoiding cancer through collective behaviour	254
The evolution of cancer and ageing: a history of constraint	229
Tertiary lymphoid structures as hubs of antitumour immunity	225
How medical anthropology can contribute to cancer research	223
Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma	221
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel	215

Epithelial and stromal co-evolution and complicity in pancreatic cancer	206
Nanoreceptors take down mutant p53	205
Impersonating neurons	201
Tumour EVPs disrupt liver function	196
AACR 2025	194
Measuring HLA disruption using MHC Hammer	192
Gut microbes produce novel genotoxic metabolites	187
Thelpers? More like Ttroublemakers	186
Persistence is key	186
Dendritic cells rise and shine	182
Removing barriers to address sex differences in anticancer drug toxicity	175
Moonlighting functions of glucose metabolic enzymes and metabolites in cancer	172
How chemokines organize the tumour microenvironment	168
No mutation, tumour initiation	162
Defining a ‘cells to society’ research framework for appendiceal tumours	161
Rethinking ovarian cancer III: the past decade and future directions	159
Natural killer cells in antitumour adoptive cell immunotherapy	157
3D bioprinted cancer models: from basic biology to drug development	153
Bone voyage: immune crosstalk sets sail	145
B-ring sterols to the rescue	140
Visualizing intratumoural heterogeneity with EpicMIBI	139
Double trouble for the tumour glycocode	133
Identifying spatial cellular structures with SPACE-GM	132
In-depth organoid profiling of pancreatic cancer	125
Environmental endocrine disruptors: rethinking the origins of early-onset ER+ breast cancer	124
Context-dependent synthetic lethality — an emerging precision therapeutic approach	122
Metabolic interplays between the tumour and the host shape the tumour macroenvironment	114
Leveraging the replication stress response to optimize cancer therapy	114
Opportunities and challenges of targeting cGAS–STING in cancer	112
The path to leptomeningeal metastasis	105
The immune microenvironment of colorectal cancer	105
Linking cell mechanical memory and cancer metastasis	103
Regulatory T cells in the tumour microenvironment	101
Enhancer and metabolic rewiring by KMT2C–COMPASS or KMT2D–COMPASS family loss in cancer creates druggable vulnerabilities	101
Dynamics and specificities of T cells in cancer immunotherapy	97
Understanding and addressing race disparities in childhood cancer outcomes	95
Race influences the tumour microbiome	95
Encoding spatial tumour dynamics with Starfysh	95
Deciphering the cancer genome and epigenome	93
ER stress sparks nerve pain	85
The link between vitamin D and prostate cancer	83
Being in the zone	83
Re-routing IgE for cancer therapy	80
Stem cells as an essential mediator of the exercise–tumorigenesis link	77
Advancing AI for multi-omics and clinical data integration in basic and translational cancer research	74
Polygenic scores in cancer	71
RNA splicing dysregulation and the hallmarks of cancer	70
Beat it!	70
Targeted protein degradation for cancer therapy	69
Cancer nanomedicine	68

Detection of cytokine-responsive cells using CyCLoPs	68
Acetyl-CoA metabolism in cancer	67
Z-nucleic acids give immunotherapy a boost	66
Prime editing GEMMs to model cancer mutations	64
Tamoxifen takes the wheel	64
Local CAR manufacturing	64
When the time is right	62
Integrative medicine in oncology: redefining the standard of care	62
Right ON target: a new RAS-GTP inhibitor	61
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities	60
Expanding the utility of precision oncology knowledge bases	60
NOTUM-mediated stem cell competition in CRC	60
Chromothripsis in cancer	56
Decoding cancer across scales with metabolomics	55
Tertiary lymphoid structures in anticancer immunity	55
Defining precancer: a grand challenge for the cancer community	55
In vivo labelling system to study cell neighbourhoods	53
Revealing genomic secrets of archival FFPE samples	52
Judith Campisi (1948–2024)	52
New pathogen on the block	51
Inferring cancer metabolism from gene-expression data	49
Melanomagenesis antagonizes stem cell ageing	48
N6-Methyladenosine: an RNA modification as a central regulator of cancer	47
Regulation of immune checkpoint molecules in cancer immune evasion and therapy	46
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart	42
The present and future of the Cancer Dependency Map	41
Cancer risk in children with congenital anomalies	39
Recent advances in therapeutic cancer vaccines	39
Transfer RNAs as dynamic and critical regulators of cancer progression	38
Carcinogenesis at single-cell resolution	38
Global post-mortem tissue donation programmes to accelerate cancer research	38
Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy	38
Patient-derived organoids unveil sarcoma vulnerabilities	37
A timeline of tumour-associated macrophage biology	36
Epigenomic heterogeneity as a source of tumour evolution	36
Focusing on the complex and dynamic interplay between ageing and cancer	36
Traject3d for studying 3D cellular heterogeneity	34
Digitally enhanced Raman spectroscopy	33
Author Correction: Integrative medicine in oncology: redefining the standard of care	32
Targeting cancer cell dormancy	31
Fcγ receptors and immunomodulatory antibodies in cancer	31
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity	30
Harnessing the influenza virus to fight cancer	30
Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity	28
We cannot ignore the cancer risks of wildfires	27
Structural variations in cancer and the 3D genome	27
Mechanisms, challenges and opportunities for FLASH radiotherapy in cancer	25
Guardrails for the use of generalist AI in cancer care	24
mRNA-based cancer therapeutics	24
Neuro-immune cross-talk in cancer	24
CAFs promote CRPC	23
Next-generation epidemiologic cohorts for cancer aetiology	23
AACR 2024	23
Modelling and deciphering tumour metabolism in CRISPR screens	22
The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment	22
Male melanoma comes of age	22
Fungi in cancer: not such a ‘fun-guy’	20
Decoding the functional impact of the cancer genome through protein–protein interactions	20
Mechanisms driving the immunoregulatory function of cancer cells	19
EMT in chemoresistance	19
Advances in cutaneous squamous cell carcinoma	18
Key role for microbiota in gut–bone crosstalk	17
Decoding the basis of histological variation in human cancer	17
Advances in translational research of the rare cancer type adrenocortical carcinoma	16
Energizing leukaemia	14
Same same but different	14
Author Correction: Learning to distinguish progressive and non-progressive ductal carcinoma in situ	13
Multiomics-guided cellular immunotherapies	12
l-Fucose: a dietary sugar with multifaceted potential in the biology and therapy of cancer	12
Inherited resilience	12
Inflammatory neutrophils	12
Deep tissue imaging of cancer in the infrared	12
Glioblastomas remodel neural circuits	11
Stemness in solid malignancies: coping with immune attack	11
Artificial intelligence-generated synthetic data for cancer research and clinical trials	11
Therapeutic resistance to anti-oestrogen therapy in breast cancer	11
Message in a vesicle: T cells boost tumour immunity	11
Mapping out mitochondria	10
Enhanced transposable elements	10
Too much of a good thing	10

Overcoming heterogeneity with 3D whole-tumour sampling	9
Addressing the gaps in cancer screening for LGBTQ+ individuals	9
Black voices in cancer research and oncology	9
Aristolochic acid-associated cancers: a public health risk in need of global action	9
Targeting sex steroid biosynthesis for breast and prostate cancer therapy	8
Limiting bias in AI models for improved and equitable cancer care	8
Air pollution promotes tumorigenesis through pre-existing oncogenic mutations	7
Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection	7
Nucleotide metabolism: a pan-cancer metabolic dependency	7
Intercepting gastric cancer	7
Pathogenesis of cancers derived from thyroid follicular cells	7
Big data in basic and translational cancer research	7
Breast milk for breast cancer detection	7
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment	7
Androgen receptor activation for breast cancer therapy	7
Fungi in cancer	7
A fatty competitor in tumour immunity	7
Feeding latent brain metastasis	7
Defining and using immune archetypes to classify and treat cancer	6
Microbiota and immune-related adverse events in cancer immunotherapy	6
Modelling the ageing dependence of cancer evolutionary trajectories	6
Conventional chemotherapy: millions of cures, unresolved therapeutic index	6
Tumour avatars to model patients’ responses to immunotherapy	6
Proximity labelling to study chromatin interactomes	6
Functional m6A site detection by FOCAS	6
Obesity as a promoter in BRCA mutation carriers	5
The fibroinflammatory response in cancer	5
Epigenetic memory	5
Small speckles, big impact	5
Understanding tumour endothelial cell heterogeneity and function from single-cell omics	5
Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma	4
A machine learning toolkit for subtyping cancer in existing and new datasets	4
Exploiting temporal aspects of cancer immunotherapy	4
Replication timings affect the frequency of chromosomal translocation	4
scAtlasVAE: a deep learning framework for generating a human CD8+ T cell atlas	4
Multiplex protein imaging in tumour biology	4
Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications	4
Protection against tumour formation	4
VIBRANT: mapping cell phenotypes using vibrational spectroscopy	4
Tracing the evolutionary history of breast cancer	4
Targeting the roots of myeloid malignancies with T cell receptors	4
Heard immunity in CAR T cells	3
Aggregating premalignancy	3
Taking a detour	3
Oncologists must act to manage cancer detected through prenatal screening	3
Cancer’s sensory experience	3
Advancing cancer research via comparative oncology	3
Allies in the epidermis	3
PDX models for functional precision oncology and discovery science	3
Phosphoinositide kinases in cancer: from molecular mechanisms to therapeutic opportunities	3
The dynamic role of platelets in cancer progression and their therapeutic implications	3
Ageing lipids map melanoma’s journey	3
Identification, functional insights and therapeutic targeting of EMT tumour states	3
Targeting aberrant splicing	3
Mastering the use of cellular barcoding to explore cancer heterogeneity	3
Targeting the tumour’s little helpers	3
Stromal cells drive tumorigenesis in BRCA1 mutation carriers	3
Lactate gives a sour taste	3
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance	3
Lymphatic vessels in the age of cancer immunotherapy	3
Rusting away with age	3
Epigenetic lesions drive gliomagenesis	3
Author Correction: The importance of 3D fibre architecture in cancer and implications for biomaterial model design	3
How protons pave the way to aggressive cancers	3
NET-working under stress	3
Hidden epithelial subtypes refine colorectal cancer classification	3
Sex affects cancer genomes	3
Salmonella, the insidious contributor to gallbladder and colon cancers	2
Liquid biopsies for Hodgkin lymphoma	2
Gender and sex interactions are intrinsic components of cancer phenotypes	2
A guide to transcriptomic deconvolution in cancer	2
Investigating immune cells across time in vivo	2
Circular RNA in cancer	2
Towards targeting transposable elements for cancer therapy	2
Cancer progression through the lens of age-induced metabolic reprogramming	2
Translating p53-based therapies for cancer into the clinic	2
Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment	2
The rise of spatial insights into tumour tissue architecture	2
Pressing defence	2
Activated neutrophils: the anti-hero	2
Approaching cancer during pregnancy	2
STAT proteins in cancer: orchestration of metabolism	2
Challenging the status quo to improve the translational potential of preclinical oncology studies	2
Why do patients with cancer die?	2
Cancers make their own luck: theories of cancer origins	2
Preprints as tools to advance careers	2
Managing cancer following the World Trade Center disaster	2
Tracking genome evolution following p53 inactivation	2
Shared immunosuppressive mechanism between pregnancy and cancer	2
Characterization of the B cell receptor repertoire in melanoma	2
Eph receptors and ephrins in cancer progression	2
Programming immune escape	2
Mesenchymal stromal/stem cells in tumour initiation, progression and therapy	2
The advent of immune stimulating CAFs in cancer	2
Tumour hypoxia in driving genomic instability and tumour evolution	2